These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 33677004)
1. Response to "Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months". Villani A; Fabbrocini G; Costa C; Scalvenzi M J Am Acad Dermatol; 2021 Jun; 84(6):e299-e300. PubMed ID: 33677004 [No Abstract] [Full Text] [Related]
2. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. Dummer R; Lear JT; Guminski A; Leow LJ; Squittieri N; Migden M J Am Acad Dermatol; 2021 Apr; 84(4):1162-1164. PubMed ID: 33358380 [No Abstract] [Full Text] [Related]
3. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394 [TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507 [TBL] [Abstract][Full Text] [Related]
5. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Chen L; Silapunt S; Migden MR Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494 [TBL] [Abstract][Full Text] [Related]
6. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810 [TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Chen L; Aria AB; Silapunt S; Lee HH; Migden MR Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833 [TBL] [Abstract][Full Text] [Related]
8. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. Gutzmer R; Robert C; Loquai C; Schadendorf D; Squittieri N; Arntz R; Martelli S; Dummer R BMC Cancer; 2021 Nov; 21(1):1244. PubMed ID: 34798846 [TBL] [Abstract][Full Text] [Related]
9. Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas. Tarantino V; Zavattaro E; Veronese F; Gironi LC; Savoia P Anticancer Drugs; 2021 Apr; 32(4):465-468. PubMed ID: 33534224 [TBL] [Abstract][Full Text] [Related]
10. Concomitant medication use does not appear to alter long-term efficacy of sonidegib for advanced basal cell carcinoma: a post hoc analysis based on the 42-month BOLT study. Lear JT; Robert C; Grob JJ; Dummer R; Guminski A; Squittieri N; Migden M Eur J Dermatol; 2023 Jun; 33(3):280-286. PubMed ID: 37594336 [TBL] [Abstract][Full Text] [Related]
12. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567 [TBL] [Abstract][Full Text] [Related]
13. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Danial C; Sarin KY; Oro AE; Chang AL Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616 [TBL] [Abstract][Full Text] [Related]
14. Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma. Burness CB; Scott LJ Target Oncol; 2016 Apr; 11(2):239-46. PubMed ID: 26867946 [TBL] [Abstract][Full Text] [Related]
15. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Collier NJ; Ali FR; Lear JT Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236 [TBL] [Abstract][Full Text] [Related]
16. Sonidegib efficacy and tolerability in advanced basal cell carcinoma: A single-center real-life experience. Villani A; Fabbrocini G; Costa C; Scalvenzi M J Am Acad Dermatol; 2022 Apr; 86(4):e175. PubMed ID: 34838876 [No Abstract] [Full Text] [Related]
17. Sonidegib (Odomzo) for basal cell carcinoma. Med Lett Drugs Ther; 2016 Feb; 58(1489):31-2. PubMed ID: 26938701 [No Abstract] [Full Text] [Related]